Transgene SA (TNG.PA)
EUR 0.71
(-1.8%)
EUR 0.71
(-1.8%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.18 Million EUR | -62.12% |
| 2022 | 3.12 Million EUR | -68.72% |
| 2021 | 9.99 Million EUR | 235.22% |
| 2020 | 2.98 Million EUR | -55.19% |
| 2019 | 6.65 Million EUR | 398.28% |
| 2018 | 1.33 Million EUR | -36.4% |
| 2017 | 2.09 Million EUR | -10.53% |
| 2016 | 2.34 Million EUR | 60.14% |
| 2015 | 1.46 Million EUR | -41.16% |
| 2014 | 2.49 Million EUR | -35.31% |
| 2013 | 3.84 Million EUR | -2.01% |
| 2012 | 3.92 Million EUR | -72.81% |
| 2011 | 14.44 Million EUR | 2.37% |
| 2010 | 14.11 Million EUR | 19.95% |
| 2009 | 11.76 Million EUR | -15.66% |
| 2008 | 13.94 Million EUR | -50.22% |
| 2007 | 28.01 Million EUR | 405.21% |
| 2006 | 5.54 Million EUR | 0.0% |
| 2004 | 2.51 Million EUR | 0.52% |
| 2003 | 2.5 Million EUR | 13.37% |
| 2002 | 2.2 Million EUR | 75.08% |
| 2001 | 1.26 Million EUR | -73.33% |
| 2000 | 4.72 Million EUR | 9.23% |
| 1999 | 4.32 Million EUR | -62.93% |
| 1998 | 11.66 Million EUR | 73.84% |
| 1997 | 6.71 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 23 Thousand EUR | 0.0% |
| 2023 Q1 | 2.38 Million EUR | 187.62% |
| 2023 Q4 | 1.56 Million EUR | 0.0% |
| 2023 Q3 | 1.56 Million EUR | 35.68% |
| 2023 Q2 | 1.15 Million EUR | -51.46% |
| 2023 FY | 1.18 Million EUR | -62.12% |
| 2022 Q2 | 2.29 Million EUR | -24.49% |
| 2022 Q1 | 3.04 Million EUR | -64.74% |
| 2022 Q4 | 828 Thousand EUR | -61.1% |
| 2022 FY | 3.12 Million EUR | -68.72% |
| 2022 Q3 | 2.12 Million EUR | -7.38% |
| 2021 Q3 | 6.12 Million EUR | 350.04% |
| 2021 FY | 9.99 Million EUR | 235.22% |
| 2021 Q2 | 1.36 Million EUR | -45.44% |
| 2021 Q4 | 8.63 Million EUR | 40.93% |
| 2021 Q1 | 2.49 Million EUR | 243.6% |
| 2020 Q1 | 2.61 Million EUR | -49.6% |
| 2020 Q4 | 726 Thousand EUR | -66.57% |
| 2020 Q3 | 2.17 Million EUR | -3.7% |
| 2020 Q2 | 2.25 Million EUR | -13.77% |
| 2020 FY | 2.98 Million EUR | -55.19% |
| 2019 Q4 | 5.18 Million EUR | 19.27% |
| 2019 Q3 | 4.35 Million EUR | 197.37% |
| 2019 FY | 6.65 Million EUR | 398.28% |
| 2019 Q1 | 2.29 Million EUR | 26.17% |
| 2019 Q2 | 1.46 Million EUR | -36.32% |
| 2018 FY | 1.33 Million EUR | -36.4% |
| 2018 Q1 | 1.72 Million EUR | -13.01% |
| 2018 Q2 | 1.72 Million EUR | 0.0% |
| 2018 Q4 | 1.82 Million EUR | 0.0% |
| 2018 Q3 | 1.82 Million EUR | 5.81% |
| 2017 Q3 | 1.97 Million EUR | 13.06% |
| 2017 Q1 | 1.75 Million EUR | -30.73% |
| 2017 Q2 | 1.75 Million EUR | 0.0% |
| 2017 FY | 2.09 Million EUR | -10.53% |
| 2017 Q4 | 1.97 Million EUR | 0.0% |
| 2016 Q2 | 2.43 Million EUR | 0.0% |
| 2016 Q1 | 2.43 Million EUR | 13.11% |
| 2016 Q3 | 2.52 Million EUR | 3.65% |
| 2016 FY | 2.34 Million EUR | 60.14% |
| 2016 Q4 | 2.52 Million EUR | 0.0% |
| 2015 Q3 | 2.15 Million EUR | -17.98% |
| 2015 Q2 | 2.62 Million EUR | 0.0% |
| 2015 Q4 | 2.15 Million EUR | 0.0% |
| 2015 FY | 1.46 Million EUR | -41.16% |
| 2015 Q1 | 2.62 Million EUR | 4.58% |
| 2014 FY | 2.49 Million EUR | -35.31% |
| 2014 Q4 | 2.51 Million EUR | 0.0% |
| 2014 Q3 | 2.51 Million EUR | -17.27% |
| 2014 Q2 | 3.03 Million EUR | 0.0% |
| 2014 Q1 | 3.03 Million EUR | -32.67% |
| 2013 Q2 | 3.35 Million EUR | 0.0% |
| 2013 FY | 3.84 Million EUR | -2.01% |
| 2013 Q4 | 4.51 Million EUR | 0.0% |
| 2013 Q1 | 3.35 Million EUR | -3.91% |
| 2013 Q3 | 4.51 Million EUR | 34.36% |
| 2012 Q4 | 3.49 Million EUR | 0.0% |
| 2012 Q3 | 3.49 Million EUR | 0.0% |
| 2012 FY | 3.92 Million EUR | -72.81% |
| 2011 FY | 14.44 Million EUR | 2.37% |
| 2010 FY | 14.11 Million EUR | 19.95% |
| 2009 FY | 11.76 Million EUR | -15.66% |
| 2008 FY | 13.94 Million EUR | -50.22% |
| 2007 FY | 28.01 Million EUR | 405.21% |
| 2006 FY | 5.54 Million EUR | 0.0% |
| 2005 Q2 | 1.08 Million EUR | 7.35% |
| 2005 Q1 | 1.01 Million EUR | 42.1% |
| 2004 Q2 | 434.8 Thousand EUR | -33.46% |
| 2004 Q1 | 653.43 Thousand EUR | 4.45% |
| 2004 Q3 | 832.52 Thousand EUR | 91.47% |
| 2004 Q4 | 713.68 Thousand EUR | -14.27% |
| 2004 FY | 2.51 Million EUR | 0.52% |
| 2003 FY | 2.5 Million EUR | 13.37% |
| 2003 Q4 | 625.59 Thousand EUR | 12.43% |
| 2003 Q2 | 424.08 Thousand EUR | -52.63% |
| 2003 Q3 | 556.43 Thousand EUR | 31.21% |
| 2003 Q1 | 895.34 Thousand EUR | -43.86% |
| 2002 Q4 | 1.59 Million EUR | 281.64% |
| 2002 FY | 2.2 Million EUR | 75.08% |
| 2002 Q1 | 82.53 Thousand EUR | -76.33% |
| 2002 Q2 | 110.36 Thousand EUR | 33.73% |
| 2002 Q3 | 417.88 Thousand EUR | 278.63% |
| 2001 Q3 | 137.25 Thousand EUR | -18.74% |
| 2001 Q1 | 602.94 Thousand EUR | -63.47% |
| 2001 FY | 1.26 Million EUR | -73.33% |
| 2001 Q4 | 348.61 Thousand EUR | 153.98% |
| 2001 Q2 | 168.91 Thousand EUR | -71.99% |
| 2000 Q2 | 1.7 Million EUR | 134.44% |
| 2000 Q4 | 1.65 Million EUR | 162.92% |
| 2000 FY | 4.72 Million EUR | 9.23% |
| 2000 Q3 | 627.81 Thousand EUR | -63.24% |
| 2000 Q1 | 728.41 Thousand EUR | -14.38% |
| 1999 Q3 | 751.18 Thousand EUR | -40.41% |
| 1999 FY | 4.32 Million EUR | -62.93% |
| 1999 Q4 | 850.77 Thousand EUR | 13.26% |
| 1999 Q1 | 1.48 Million EUR | -57.2% |
| 1999 Q2 | 1.26 Million EUR | -14.94% |
| 1998 FY | 11.66 Million EUR | 73.84% |
| 1998 Q1 | 7.94 Million EUR | 0.0% |
| 1998 Q2 | 646.03 Thousand EUR | -91.87% |
| 1998 Q3 | 427.27 Thousand EUR | -33.86% |
| 1998 Q4 | 3.46 Million EUR | 710.45% |
| 1997 FY | 6.71 Million EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.64 Million EUR | 74.483% |
| ABIVAX Société Anonyme | 4.62 Million EUR | 74.378% |
| Adocia SA | 2.15 Million EUR | 44.93% |
| Aelis Farma SA | 9.05 Million EUR | 86.923% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 3.15 Million EUR | 62.425% |
| genOway Société anonyme | 20.04 Million EUR | 94.094% |
| IntegraGen SA | 12.53 Million EUR | 90.556% |
| Medesis Pharma S.A. | 300.03 Thousand EUR | -294.622% |
| Neovacs S.A. | 533.41 Thousand EUR | -121.967% |
| NFL Biosciences SA | - EUR | -Infinity% |
| Plant Advanced Technologies SA | 1.68 Million EUR | 29.587% |
| Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -5881.006% |
| Sensorion SA | 4.74 Million EUR | 75.037% |
| Theranexus Société Anonyme | 296.33 Thousand EUR | -299.553% |
| TME Pharma N.V. | 17 Thousand EUR | -6864.706% |
| Valbiotis SA | 4.73 Million EUR | 74.984% |
| TheraVet SA | 1.07 Million EUR | -9.827% |
| Valerio Therapeutics Société anonyme | 1.8 Million EUR | 34.222% |
| argenx SE | 1.13 Billion EUR | 99.896% |
| BioSenic S.A. | 543 Thousand EUR | -118.048% |
| Celyad Oncology SA | 102 Thousand EUR | -1060.784% |
| DBV Technologies S.A. | - EUR | -Infinity% |
| Galapagos NV | 239.72 Million EUR | 99.506% |
| Genfit S.A. | 28.56 Million EUR | 95.855% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | 43.268% |
| Innate Pharma S.A. | 51.9 Million EUR | 97.719% |
| Inventiva S.A. | 17.47 Million EUR | 93.225% |
| MaaT Pharma SA | 2.22 Million EUR | 46.858% |
| MedinCell S.A. | 9.16 Million EUR | 87.074% |
| Nanobiotix S.A. | 30.05 Million EUR | 96.061% |
| Onward Medical N.V. | 532 Thousand EUR | -122.556% |
| Oryzon Genomics S.A. | 14.19 Million EUR | 91.657% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | 46.834% |
| Oxurion NV | 263 Thousand EUR | -350.19% |
| Pharming Group N.V. | 245.31 Million EUR | 99.517% |
| Poxel S.A. | 1.98 Million EUR | 40.232% |
| GenSight Biologics S.A. | 1.26 Million EUR | 6.551% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 99.977% |
| Valneva SE | 153.71 Million EUR | 99.23% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 132.707% |